These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 28476338)

  • 1. Corrigendum to "self-reported cannabis use is inconsistent with the results from drug-screening in youth at ultra high-risk for psychosis in Colorado" [Schizophr. Res. 157 (0) (August 2014) 317-318].
    Carol EE; Mittal VA
    Schizophr Res; 2018 Feb; 192():494. PubMed ID: 28476338
    [No Abstract]   [Full Text] [Related]  

  • 2. Corrigendum to "Neuroanatomical correlates of perceptual aberrations in psychosis" [Schizophr. Res. 179 (2017) 125-131].
    Brosey EA; Woodward ND
    Schizophr Res; 2018 Jul; 197():624. PubMed ID: 29699896
    [No Abstract]   [Full Text] [Related]  

  • 3. Corrigendum to "abnormal white matter integrity in antipsychotic-naïve first-episode psychosis patients assessed by a DTI principal component analysis" [Schizophr. Res. 162 (1-3) (march 2015) 14-21].
    Alvarado-Alanis P; León-Ortiz P; Reyes-Madrigal F; Favila R; Rodríguez-Mayoral O; Nicolini H; Azcárraga M; Graff-Guerrero A; Rowland LM; de la Fuente-Sandoval C
    Schizophr Res; 2016 Oct; 176(2-3):582. PubMed ID: 27264503
    [No Abstract]   [Full Text] [Related]  

  • 4. Corrigendum to "Therapeutic Effectiveness and Tolerability of Aripiprazole as Initial Choice of Treatment in First Episode Psychosis in an Early Intervention Service: A One-Year Outcome Study" [Schizophr. Res. 147, 120-125].
    Malla A; Mustafa S; Rho A; Abadi S; Lepage M; Joober R
    Schizophr Res; 2018 Mar; 193():490. PubMed ID: 29550056
    [No Abstract]   [Full Text] [Related]  

  • 5. Corrigendum to "Long-term hospitalizations for schizophrenia in the Czech Republic 1998-2012" (Schizophr. Res. vol. 175, issues 1-3, August 2016, pages 180-185).
    PetrWinkler ; Mladá K; Krupchanka D; Agius M; Ray MK; Höschl C
    Schizophr Res; 2016 Oct; 176(2-3):581. PubMed ID: 27476650
    [No Abstract]   [Full Text] [Related]  

  • 6. Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis.
    Kraan T; Velthorst E; Koenders L; Zwaart K; Ising HK; van den Berg D; de Haan L; van der Gaag M
    Psychol Med; 2016 Mar; 46(4):673-81. PubMed ID: 26568030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum to "Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study" [Schizophr. Res. volume 225 (May 2023) 173-181].
    Millgate E; Smart SE; Pardiñas AF; Kravariti E; Ajnakina O; Kępińska AP; Andreassen OA; Barnes TRE; Berardi D; Crespo-Facorro B; D'Andrea G; Demjaha A; Di Forti M; Doody GA; Üçok A; Kassoumeri L; Ferchiou A; Guidi L; Joyce EM; Lastrina O; Melle I; Pignon B; Richard JR; Simonsen C; Szöke A; Tarricone I; Tortelli A; Vázquez-Bourgon J; Murray RM; Walters JTR; MacCabe JH;
    Schizophr Res; 2024 Aug; 270():495-496. PubMed ID: 39079354
    [No Abstract]   [Full Text] [Related]  

  • 8. Cannabis-induced attenuated psychotic symptoms: implications for prognosis in young people at ultra-high risk for psychosis.
    McHugh MJ; McGorry PD; Yung AR; Lin A; Wood SJ; Hartmann JA; Nelson B
    Psychol Med; 2017 Mar; 47(4):616-626. PubMed ID: 27821204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between cannabis use and cortisol levels in youth at ultra high-risk for psychosis.
    Carol EE; Spencer RL; Mittal VA
    Psychoneuroendocrinology; 2017 Sep; 83():58-64. PubMed ID: 28595088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum to "Self and time in individuals with schizophrenia: A motor component?" [Schizophr. Res. 272 (2024) 12-19 (October)].
    Foerster FR; Joos E; Martin B; Coull JT; Giersch A
    Schizophr Res; 2024 Oct; 274():269. PubMed ID: 39395269
    [No Abstract]   [Full Text] [Related]  

  • 11. Cannabis use is not associated with the development of psychosis in an 'ultra' high-risk group.
    Phillips LJ; Curry C; Yung AR; Yuen HP; Adlard S; McGorry PD
    Aust N Z J Psychiatry; 2002 Dec; 36(6):800-6. PubMed ID: 12406123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum to cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment [Schizophr. Res. 168 (2015) 587-588].
    van de Bilt MT; Prado CM; Ojopi EPB; de Sousa RT; Loch AA; Zanetti MV; Talib LL; Gattaz WF
    Schizophr Res; 2016 Jul; 174(1-3):204. PubMed ID: 27066861
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to "Phenotype continuum between autism and schizophrenia: Evidence from the Movie for the Assessment of the social cognition (MASC)" [Schizophr. Res. 185 (2017) 161-166].
    Martinez G; Alexandre C; Mam-Lam-Fook C; Bendjemaa N; Gaillard R; Garel P; Dziobek I; Amado I; Krebs MO
    Schizophr Res; 2018 Mar; 193():489. PubMed ID: 29550055
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "Development of a new measure for assessing insight: Psychometric properties of the insight orientation scale (IOS)" [Schizophr. Res. 169 (2015) 298-302].
    Gori A; Craparo G; Giannini M; Loscalzo Y; Caretti V; La Barbera D; Manzoni GM; Castelnuovo G; Tani F; Ponti L; Dewey D; Schuldberg D
    Schizophr Res; 2016 Apr; 172(1-3):227. PubMed ID: 27040093
    [No Abstract]   [Full Text] [Related]  

  • 15. Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls.
    Korver N; Nieman DH; Becker HE; van de Fliert JR; Dingemans PH; de Haan L; Spiering M; Schmitz N; Linszen DH
    Aust N Z J Psychiatry; 2010 Mar; 44(3):230-6. PubMed ID: 20180725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabis use and vulnerability for psychosis in early adolescence--a TRAILS study.
    Griffith-Lendering MF; Wigman JT; Prince van Leeuwen A; Huijbregts SC; Huizink AC; Ormel J; Verhulst FC; van Os J; Swaab H; Vollebergh WA
    Addiction; 2013 Apr; 108(4):733-40. PubMed ID: 23216690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corrigendum to "Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies" [Schizophr. Res. 174 (2016) 82-92].
    Correll CU; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Kane JM
    Schizophr Res; 2017 Dec; 190():191-194. PubMed ID: 28351543
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to "Increased diffusivity in gray matter in recent onset schizophrenia is associated with clinical symptoms and social cognition" [Schizophr. Res. 176 (2-3) (Oct 2016) 144-150].
    Lee JS; Kim CY; Joo YH; Newell D; Bouix S; Shenton ME; Kubicki M
    Schizophr Res; 2017 Mar; 181():137. PubMed ID: 27890401
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "resilience in schizophrenia: A comparative study between a remote island and an urban area in Japan" [Schizophr. Res. Volume 171, Issues 1-3, March 2016, Pages 92-96].
    Yoshida K; Suzuki T; Imasaka Y; Kubo KI; Mizuno Y; Saruta J; Tsukinoki K; Mimura M; Uchida H
    Schizophr Res; 2016 Oct; 176(2-3):580. PubMed ID: 27539074
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "The danger of averages in the context of heterogeneity: Response to the letter to the editor of SCZ RES - role of ECT in patients with CRS - Markota et al., 2024" [Schizophr. Res. 269 (2024): 120-122].
    Elkis H
    Schizophr Res; 2024 Sep; ():. PubMed ID: 39232890
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.